[{"data":1,"prerenderedAt":197},["ShallowReactive",2],{"drug-tamoxifen":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":43,"contraindications":82,"warnings":92,"renal":100,"monitoring":101,"interactions":102,"review":110,"examples":113,"atc":122,"iran":124,"usApproval":140,"links":146,"populations":162},"tamoxifen",1,{"fa":7,"en":8},"تاموکسیفن","Tamoxifen","antineoplastic-immunomodulating",{"fa":11,"en":12},"تعدیل‌کننده انتخابی گیرنده استروژن (SERM)","Selective estrogen receptor modulator (SERM)",[14],{"name":15,"market":16},"Nolvadex","US",[18,7,19],"nolvadex","نولوادکس",[21,35],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":30,"refs":31},"tab-10","tablet","oral","10 mg tablet",{"amount":27,"unit":28,"perUnit":23,"scored":29},10,"mg",false,[16],[32],{"source":33,"section":34},"fda-tamoxifen","How Supplied",{"id":36,"form":23,"route":24,"label":37,"concentration":38,"markets":40,"refs":41},"tab-20","20 mg tablet",{"amount":39,"unit":28,"perUnit":23,"scored":29},20,[16],[42],{"source":33,"section":34},[44,72],{"id":45,"disease":46,"label":47,"population":50,"type":54,"unit":28,"dose":55,"refs":56,"notes":59},"bc","breast-cancer",{"fa":48,"en":49},"سرطان پستان — ۲۰ تا ۴۰ mg در روز (بالای ۲۰ mg در دو دوز)","Breast cancer — 20–40 mg\u002Fday (above 20 mg in two doses)",{"minAge":51},{"value":52,"unit":53},18,"year","fixed",{"perDose":39,"dosesPerDay":5},[57],{"source":33,"section":58},"Dosage and Administration",[60,66],{"text":61,"refs":64},{"fa":62,"en":63},"فقط زیر نظر متخصص انکولوژی؛ دوز بر اساس پاسخ و عوارض تنظیم می‌شود.","Only under an oncologist; dose is adjusted by response and toxicity.",[65],{"source":33,"section":58},{"text":67,"refs":70},{"fa":68,"en":69},"دوز بالای ۲۰ mg\u002Fروز صبح و عصر. درمان کمکی معمولاً ۵ سال.","Doses above 20 mg\u002Fday split morning and evening. Adjuvant therapy usually 5 years.",[71],{"source":33,"section":58},{"id":73,"disease":46,"label":74,"population":77,"type":54,"unit":28,"dose":79,"refs":80},"dcis",{"fa":75,"en":76},"DCIS و کاهش خطر در زن پرخطر — ۲۰ mg روزانه ۵ سال","DCIS and risk reduction in high-risk women — 20 mg daily for 5 years",{"minAge":78},{"value":52,"unit":53},{"perDose":39,"dosesPerDay":5},[81],{"source":33,"section":58},[83],{"id":84,"severity":85,"text":86,"refs":89},"ci","block",{"fa":87,"en":88},"حساسیت به تاموکسیفن. DCIS و کاهش خطر: نیاز به ضدانعقاد کومارینی یا سابقه DVT یا آمبولی ریه.","Hypersensitivity to tamoxifen. DCIS and risk reduction: need for coumarin anticoagulants or history of DVT or pulmonary embolism.",[90],{"source":33,"section":91},"Contraindications",[93],{"text":94,"refs":97},{"fa":95,"en":96},"هشدار جعبه‌ای (DCIS و کاهش خطر): بدخیمی رحم، سکته مغزی و آمبولی ریه — گاه کشنده.","Boxed warning (DCIS and risk reduction): uterine malignancies, stroke and pulmonary embolism — sometimes fatal.",[98],{"source":33,"section":99},"Boxed Warning",[],[],[103],{"with":104,"text":105,"refs":108},"warfarin",{"fa":106,"en":107},"وارفارین: افزایش شدید اثر ضدانعقادی.","Warfarin: marked increase in anticoagulant effect.",[109],{"source":33,"section":91},{"status":111,"reviewer":112,"date":112},"unverified",null,[114,119],{"regimen":45,"formulation":36,"input":115,"expect":118},{"ageYears":116,"weightKg":117},50,65,{"perDose":39,"tabletsPerDoseRounded":5},{"regimen":73,"formulation":36,"input":120,"expect":121},{"ageYears":116,"weightKg":117},{"perDose":39,"tabletsPerDoseRounded":5},[123],"L02BA01",{"status":125,"forms":126,"refs":135},"registered",[127,131],{"code":128,"en":129,"fa":130},"01193","TAMOXIFEN CITRATE 10MG TAB","قرص تاموکسیفن سیترات ۱۰ میلی‌گرم",{"code":132,"en":133,"fa":134},"02465","TAMOXIFEN CITRATE 20MG TAB","قرص تاموکسیفن سیترات ۲۰ میلی‌گرم",[136],{"source":137,"section":138,"url":139},"darooyab-generic","G-1070\u002FTamoxifen","https:\u002F\u002Fwww.darooyab.ir\u002FG-1070\u002FTamoxifen",{"kind":141,"refs":142,"id":145},"ANDA",[143],{"source":33,"section":144},"SPL approval \u002F marketing category","ANDA074732",[147,150,154,157,160],{"kind":148,"url":149,"label":145},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=074732",{"kind":151,"url":152,"label":153},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0","FDA Tamoxifen",{"kind":155,"url":156,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa682414.html",{"kind":158,"url":159,"label":123},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=L02BA01",{"kind":161,"url":139,"label":8},"darooyab",{"pregnancy":163,"lactation":172,"pediatric":180,"geriatric":189},{"level":164,"text":165,"quote":168,"refs":169},"avoid",{"fa":166,"en":167},"برچسب: می‌تواند به جنین آسیب بزند. در بارداری خطرناک است.","Label: can cause fetal harm. Dangerous in pregnancy.","Pregnancy Category D Tamoxifen may cause fetal harm when administered to a pregnant woman.",[170],{"source":33,"section":171},"Pregnancy",{"level":164,"text":173,"quote":176,"refs":177},{"fa":174,"en":175},"برچسب: شیردهی توصیه نمی‌شود یا باید بین دارو و شیردهی یکی انتخاب شود.","Label: breastfeeding not recommended, or choose between the drug and breastfeeding.","Because of the potential for serious adverse reactions in nursing infants from tamoxifen, women taking tamoxifen should not breast-feed.",[178],{"source":33,"section":179},"Nursing Mothers",{"level":181,"text":182,"quote":185,"refs":186},"caution",{"fa":183,"en":184},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","The safety and efficacy of tamoxifen for girls aged 2 to 10 years with McCune-Albright Syndrome and precocious puberty have not been studied beyond one year of treatment.",[187],{"source":33,"section":188},"Pediatric Use",{"level":181,"text":190,"quote":193,"refs":194},{"fa":191,"en":192},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","A reduction in breast cancer incidence was seen among participants in each of the subsets: A total of 28 and ten invasive breast cancers were seen among participants 65 and older in the placebo and tamoxifen groups, respectively.",[195],{"source":33,"section":196},"Geriatric Use",1792156196550]